Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mauricette Michallet"'
Autor:
N Boissel, Lea Payen-Gay, Hussein Mortada, Pascale Flandrin-Gresta, Catherine Koering, Eric Wattel, Delphine Maucort-Boulch, Didier Auboeuf, Sandrine Hayette, Emeline Cros, Mohamed El-Hamri, Antony Ceraulo, Aminetou Mint Mohamed, Olivier Nibourel, Denis Guyotat, Isabelle Tigaud, Claude Preudhomme, Françoise Solly, Mauricette Michallet, Meyling Cheok, Lydia Campos, Franck-Emmanuel Nicolini, Franck Mortreux, Xavier Thomas, Christiane Pinatel, Charles Dumontet, Marie Balsat
Publikováno v:
Leukemia Research. 56:21-28
In AML, approximately one-third of expressed genes are abnormally spliced, including aberrant TET2 exon 2 expression. In a discovery cohort (n=99), TET2 exon 2 skipping (TET2E2S) was found positively associated with a significant reduction in the cum
Autor:
Aminetou Mint, Mohamed, Marie, Balsat, Catherine, Koering, Delphine, Maucort-Boulch, Nicolas, Boissel, Lea, Payen-Gay, Meyling, Cheok, Hussein, Mortada, Didier, Auboeuf, Christiane, Pinatel, Mohamed, El-Hamri, Isabelle, Tigaud, Sandrine, Hayette, Charles, Dumontet, Emeline, Cros, Pascale, Flandrin-Gresta, Olivier, Nibourel, Claude, Preudhomme, Xavier, Thomas, Franck-Emmanuel, Nicolini, Françoise, Solly, Denis, Guyotat, Lydia, Campos, Mauricette, Michallet, Antony, Ceraulo, Franck, Mortreux, Eric, Wattel
Publikováno v:
Leukemia research. 56
In AML, approximately one-third of expressed genes are abnormally spliced, including aberrant TET2 exon 2 expression. In a discovery cohort (n=99), TET2 exon 2 skipping (TET2E2S) was found positively associated with a significant reduction in the cum
Autor:
Sandrine Hayette, Kaddour Chabane, Mauricette Michallet, Michel Tulliez, Laurence Legros, Franck E. Nicolini, Françoise Rigal-Huguet, Jean-Pierre Magaud, Philippe Rousselot, Thomas Prebet, Agnès Guerci, Aude Charbonnier, Carole Paillet, Frédéric Maloisel, Christine Pivot
Publikováno v:
Leukemia Research. 35:80-86
This phase I/II study was designed to demonstrate the tolerance and the efficacy of a combination of pegylated interferon-α 2a to Imatinib mesylate (IM) 600 mg daily in cytogenetically IM-resistant but in CHR chronic phase CML patients. The combinat
Autor:
Xavier Thomas, Youcef Chelghoum, Nabaz Jaff, Mohamed Elhamri, Mauricette Michallet, Isabelle Tigaud
Publikováno v:
Leukemia Research. 31:67-73
One hundred and fifty-four acute myeloid leukemia patients with trisomy 8 were studied for their clinical and biological characteristics, and treatment outcome. Forty-seven patients presented with trisomy 8 as the sole aberration, 107 with trisomy 8
Autor:
Sandrine Hayette, Mauricette Michallet, Jean-Pierre Magaud, Marie-Laurence Baille, Franck E. Nicolini
Publikováno v:
Leukemia Research. 29:1073-1077
Quantitative monitoring of imatinib mesylate (IM)-resistant, mutated BCR-ABL(+) cells during the follow-up of CML could be useful for optimizing therapeutic management. We retrospectively analyzed T315I mutated BCR-ABL clones throughout the CML histo
Autor:
Mauricette Michallet, Aline Renneville, Sylvie Castaigne, Jean-Henri Bourhis, Hervé Dombret, Mohamed Elhamri, Nicolas Boissel, Catherine Cordonnier, Thierry de Revel, Pierre Fenaux, Oumedaly Reman, Christine Terré, Youcef Chelghoum, Emmanuel Raffoux, Bruno Quesnel, Gérard Socié, Claude Gardin, Xavier Thomas, Stéphane de Botton, Cécile Pautas, Claude Preudhomme
Publikováno v:
Leukemia research. 36(9)
Forty-seven percent of adults with acute myeloid leukemia (AML) who entered the ALFA-9802 trial and achieved a first complete remission (CR) experienced a first relapse. We examined the outcome of these 190 adult patients. Eighty-four patients (44%)
Autor:
Christian Berthou, Pascale Cony-Makhoul, Francois-Xavier Mahon, Agnès Guerci, Jean Michel Cayuela, Mauricette Michallet, Philippe Rousselot, Bénédicte Deau, Sylvie Castaigne, Delphine Rea, François Guilhot, Cécile Pautas, Denis Guyotat, Joelle Guilhot, Françoise Huguet, Laurence Legros, Martine Gardembas, Isabelle Radford–Weiss, Franck E. Nicolini, Sandrine Hayette
Publikováno v:
Leukemia research. 35(6)
Background The median survival of patients with chronic myelogenous leukemia in myeloid blast crisis (MBC-CML) is poor even for patients treated with tyrosine kinase inhibitors (TKIs). Design and methods We conducted a dose-escalating study of daunor
Autor:
Sylvie François, Mauricette Michallet, Hervé Dombret, M. Robin, N. Maillard, R. Peffault de Latour, Pierre Fenaux, Jérôme Cornillon, Alain Delmer, Reman Oumedaly, Stéphanie Nguyen, Anne Huynh, J.-O. Bay, Laure Vincent, Marie T Rubio, Lionel Adès, J.Y. Cahn, Raphaël Porcher, Aude Charbonnier, Emmanuel Raffoux, Eric Wattel, Gérard Socié, S. Vigouroux
Publikováno v:
Leukemia Research. 39:S6
sotatercept (ACE-011), a novel first-in-class activin type IIA receptor fusion protein, in anemic patients with IPSS Low/Intermediate-1risk MDS or non-proliferative CMML. ClinicalTrials.gov identifier: NCT01736683. Methods: The primary endpoint of th
Autor:
Franck E. Nicolini, Sandrine Hayette, Jean-Pierre Magaud, Isabelle Tigaud, Mauricette Michallet, Kaddour Chabane
Publikováno v:
Leukemia research. 31(6)
Dasatinib is efficient in vitro against most of CML cells harboring ABL kinase domain mutations and induces high rates of response in imatinib-resistant CML patients. Here, we monitored the mutated BCR-ABL transcripts during the follow-up of 12 CML p
Autor:
Pierre Fenaux, Noel Milpied, Natacha Maillard, A. Duhame, Jérôme Cornillon, Sylvie François, Yves Beguin, Mauricette Michallet, Patrice Chevallier, Nathalie Fegueux, Ibrahim Yakoub-Agha, Bruno Lioure, Son Nguyen, Didier Blaise, Claude-Eric Bulabois, M. Robin, G. Damaj, Marie T Rubio, Mohamad Mohty, Anne Huyn
Publikováno v:
Leukemia Research. 37:S14-S15